WHO ICTRP trial
HERMES – A research study to look at how ziltivekimab works compared to placebo…
CTRI/2023/06/053508 · Clinical Trials Registry India (CTRI) · Recruiting
Key facts
| Trial ID | CTRI/2023/06/053508 |
|---|---|
| Public title | HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. |
| Scientific title | HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation. - HERMES_EX6018-4915 |
| Primary sponsor | Novo Nordisk India Pvt Ltd |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | Bulgaria;Canada;Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;China;Colombia;Croatia;Czech… |
| Conditions | Health Condition 1: I503- Diastolic (congestive) heart failure |
| Interventions | Intervention1: Ziltivekimab: Ziltivekimab 15 mg/mL, Solution for injection, Single-use prefilled manual syringe (1 mL)- Subcutaneous for 48 months Control Intervention1: Ziltivekimab placebo: Solution for injection, Subcutaneous, Single-use… |
| Registration date | Feb 6, 2023 |
| Target size | 5600 |
| Secondary IDs | EX6018-4915,Version 3.0, 03 April 2023 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: